Ockham Biotech
Ockham Biotech is a research company focused on developing inhaled heparin for treating obstructive airway diseases such as cystic fibrosis, COPD, asthma, and bronchiectasis. They aim to commercialize inhaled heparin derivatives and are engaged in research, clinical trials, and patenting innovative therapies. The company emphasizes the potential of their compound OCK4, which has anti-inflammatory, antimicrobial, and mucus-thinning properties, to address unmet clinical needs in respiratory diseases.
Industries
Nr. of Employees
small (1-50)
Ockham Biotech
Ockham Biotech Limited, Trinity Court, 2-4 West Street, Fareham, Hampshire, PO16 0BH
Patents
Products
Nebulised heparin-analogue therapeutic for obstructive airway diseases
A nebulised heparin-derived compound formulated for pulmonary administration that aims to reduce mucus viscosity, provide antimicrobial and anti-inflammatory effects, and avoid systemic anticoagulation; development focused on cystic fibrosis, non-CF bronchiectasis and COPD.
Nebulised heparin-analogue therapeutic for obstructive airway diseases
A nebulised heparin-derived compound formulated for pulmonary administration that aims to reduce mucus viscosity, provide antimicrobial and anti-inflammatory effects, and avoid systemic anticoagulation; development focused on cystic fibrosis, non-CF bronchiectasis and COPD.
Services
In vitro and in vivo studies to characterize mucolytic, antimicrobial and anti-inflammatory activity, mechanism of action assays, and inhalation-route toxicology to support clinical entry.
Development of nebulised formulations and co-development with a mesh nebuliser manufacturer to deliver therapeutic doses rapidly and with characterized aerosol properties.
Preparatory activities for Phase IIa trials including trial design, site and regulatory preparation to obtain clearance for clinical studies of inhaled therapies.
Management and prosecution of patents covering inhaled formulations and delivery methods, PCT progression and securing orphan drug designations.
Engagement with potential commercial partners and funders to progress clinical development and plan market entry for inhaled respiratory therapies.
In vitro and in vivo studies to characterize mucolytic, antimicrobial and anti-inflammatory activity, mechanism of action assays, and inhalation-route toxicology to support clinical entry.
Development of nebulised formulations and co-development with a mesh nebuliser manufacturer to deliver therapeutic doses rapidly and with characterized aerosol properties.
Preparatory activities for Phase IIa trials including trial design, site and regulatory preparation to obtain clearance for clinical studies of inhaled therapies.
Management and prosecution of patents covering inhaled formulations and delivery methods, PCT progression and securing orphan drug designations.
Engagement with potential commercial partners and funders to progress clinical development and plan market entry for inhaled respiratory therapies.
Expertise Areas
- Inhaled therapeutics development
- Pulmonary drug delivery and aerosol science
- Pre-clinical respiratory pharmacology
- Clinical trial management for inhaled drugs (Phase II planning)
Key Technologies
- Mesh nebuliser aerosol delivery
- Aerosol aerodynamic characterization and modelling
- DNase activation assays
- Neutrophil elastase inhibition assays